Single-temperature incubation has been discussed for a long time in the pharmaceutical industry but only a few sites have implemented this system. Here, Guillaume Pinon, Head of the Microbiology Lab at Servier, discusses the use of single-temperature incubation in an aseptic production facility, outlining the regulatory considerations, strategic approach, challenges and prospects.
Single- or mono-temperature incubation is not easy to implement, but it offers efficiency and performance advantages and an opportunity to simplify the process in a pharmaceutical microbiology laboratory. This article shares our motivations, approach and experience of implementing mono-temperature incubation in our laboratories over the past several years.
Regulatory requirements
First we looked at the regulatory texts available concerning mono-temperature incubation for environmental monitoring (EM). The search was straightforward, as there is no description in pharmacopoeias or official regulatory guidance. Information can be found in certain US pharmacopeia guide chapters, such as USP <1116>,1 as well as guidance from the US Food and Drug Administration (FDA) and World Health Organization (WHO) but none of these are regulatory requirements. From this observation, all options are possible. However, adoption is not simple and one point frequently made is the need to take historical data into account. In the absence of any regulatory text, numerous presentations have been made on the subject, prompting debate and initiating reflection.2,3 Mono-temperature incubation will also receive special attention when A3P Association’s Microbiology common interest group (CIG) members carry out specific work.
Study: Strategy
To understand our choice of mono-temperature incubation, several factors need to be taken into consideration.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
The first factor is our need to develop an environmental monitoring plan for a new unit for bioproduction of monoclonal antibodies and aseptic filling under isolator. The unit comprises 2,000m2 of Grade C and D, as well as an isolator for aseptic filling.
This information eliminates the need for comparison with historical data, enabling a simpler approach to implementation. The method described below should not be discarded, however, but adapted for comparison with historical data obtained with a double-temperature incubation sequence.
The second factor is a desire to simplify and optimise the process of handling environmental controls.
These two reasons prompted us to launch a wide-ranging study comparing incubation sequences involving a multitude of strains, in order to produce sufficient data to support a solid argument for the selection of an incubation sequence.
Step 1: Culture medium selection
This first step is essential, as the selected medium must enable the recovery of multiple strains from different ecosystems (eg, human, environmental) and of different natures (eg, bacteria, yeasts, moulds). We chose the tryptone soy agar (TSA) with neutralisers medium, which allows most microorganisms to thrive thanks to its nutrient conditions.
As taxonomy is extremely diverse, varied and not yet fully understood, it is undeniable that strains do exist which are not able to grow on this medium, but it does have the nutrients required for the development of strains commonly found in a pharmaceutical environment.
Step 2: Strain selection
Strain selection was launched in two test phases.
Phase 1 involved testing 19 strains (see Table 1). Each strain was selected to take into account:
the variability of environmental and human strains in a pharmaceutical production environment
strains known for their particular growth conditions, such as growth temperature, invasiveness, growth difficulties, etc (eg, Cladosporium, specific moulds, corynebacteria, Bacillus, etc).
Phase 2 included selection of 32 new strains mainly found in the pharmaceutical industry (see Table 2). This identification was carried out in partnership with the ACM PHARMA laboratory, which performs around 35,000 identifications per year, giving us a more complete panel of different species generally encountered in the pharmaceutical industry. This selection completes the large families of strains previously tested in Phase 1. For example, a strain of Cladosporium was tested in the first phase because it was known not to grow at temperatures above 26-27°C (the worst-case strain in the study). In the second phase, two other Cladosporium strains were added to confirm the results generated. A Corynebacterium strain was also tested, as it has a growth preference for high temperatures. One species was tested in Phase 1 and supplemented by six new species in Phase 2. This multiplication of species and strains in the second phase ensures the reproducibility of the results generated for a given temperature and strain typology.
Step 3: Selection of incubation sequences
The selection of incubation temperatures was based on the data shown in Table 3.
The whole of Phase 1 (19 strains) was carried out under standard laboratory conditions, ie, incubation in ovens and manual enumeration.
In Phase 2 (addition of 32 new strains), we augmented the standard conditions with the use of an automated system for incubation and real-time reading. The system was set up for incubation at the target temperature of 25°C (based on the results of the first test phase). This new entrant provides data for an essential EM parameter: early detection of microbial growth. This element is essential for reactivity in the transmission and treatment of a contamination event in a classified area.
Results
The results of Phase 1 (see Table 4) highlight 25°C as the most effective temperature for recovery. In fact, this temperature does not inhibit growth of the Cladosporium strain, unlike 27.5°C and 30°C.
The double-temperature sequence produces less effective results in the first 48-72 hours on strains from the cockle family (one of the majority families in a classified area). This information is important, as the slower growth induced by the lower temperature at the start of incubation could, on the one hand, be a source of inhibition for fragile microorganisms and, on the other, be less compatible with early detection of contamination in the classified area.
The 25°C temperature is therefore the most effective, as it does not inhibit any strain (compared with temperatures of 27.5°C and 30°C), and of the panel tested, only one strain develops slowly (no visible colonies) in the first 48-72 hours (instead of four strains for the double temperature).
Phase 1 demonstrated that the 25°C temperature performed best, of the sequences tested, and that it was suitable for the detection of environmental microorganisms. However, the panel of strains tested was not sufficiently complete, prompting the move to Phase 2 of the study.
The second phase is still in progress on moulds and some bacteria, with 39 strains tested out of the 51. The results of Phase 2 so far show no significant difference in the behaviour of the additional strains. Each family reacted in the same way (corynebacteria, Staphylococcus, Micrococcus, Bacillus, etc). The new strains tested (eg, paracoccus yeii or paenibacillus glucanolyticus) confirm the temperature of 25°C.
These results therefore confirm that the 25°C mono-temperature can be used for environmental monitoring in our classified area, and that it produces better results in terms of detection of both human strains (sensitive to low temperatures) and environmental strains (sensitive to high temperatures).
This phase also showed that the use of an automated real-time reader facilitates earlier detection of a colony than the human eye, in most cases. (The best time gain was more than 30 hours). However, there are a few exceptions, notably certain fast-growing, fluffy moulds with no specific pigmentation, which the system fails to detect or detects very late. This technology not only ensures reactivity in detection, but also provides the opportunity, by taking snapshots during incubation, to accurately check the count if the box is invaded at the end of incubation.
Future prospects
This study shows that it is possible to choose single-temperature incubation in a pharmaceutical environment, thanks to the efficiency demonstrated in this study. The choice of incubation temperature must be based on data adapted to the specific environment. Site strains are of major interest in this context. To say that 25°C is the only valid temperature is erroneous, but in view of the data generated in our context, it remains the optimum temperature for the detection of contamination in our production environment, thus guaranteeing drug quality and, ultimately, patient safety.
Automation has proved its worth in terms of early colony detection. This point should not be overlooked, as it is crucial for contaminant detection in the classified area to rapidly implement remediation measures.
The future of environmental monitoring lies in the combination of a single incubation temperature and automation.
About the author
Guillaume Pinon
Trained as a microbiologist, Guillaume is currently in charge of the microbiology laboratory for Laboratoires SERVIER Industrie. He has worked for some 20 years for various pharmaceutical manufacturing facilities (sterile injectable and non-sterile powder, solid, liquid formulations) as well as in a laboratory specialised in microbiology for pharmaceutical, cosmetic and biotechnological quality control.
References
USP <1116> MICROBIOLOGICAL CONTROL AND MONITORING OF ASEPTIC PROCESSING ENVIRONMENTS
PDA October 2021 Thierry Bonnevay (Sanofi) and Laurent Leblanc (Biomérieux): Suitability of a Single Incubation Temperature for Environmental Monitoring Program
PDA October 2020: Linda BOELE and Arabela CUIROLO (KYTE): Selection of incubation conditions for environmental monitoring samples at TCF04-Kite pharma EU
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.